Access Exclusive Payer Research on Biosimilars

Payers expect an increase in their utilization of biosimilars compared with reference products, according to MMIT’s new Biosimilars Special Report. It found that of nine indications, payers are most likely to anticipate an increase in biosimilars for rheumatoid arthritis and breast cancer.

The report, based on an expert panel of 40 commercial managed care decision-makers and 30 Medicare managed care decision-makers (with payer names revealed), offers a holistic view of biosimilars utilization, management, contracting and transition trends.

The report covers:

  • Total prescription volume represented by biologics;
  • Biosimilar utilization changes;
  • Payers’ management decisions within immunology categories;
  • Rebate, value, volume, indication and portfolio-based contracts;
  • Biosimilar market baskets;
  • Price discounts for biosimilars; and
  • Transitions from branded reference products to biosimilar agents.

To get an expert read-out of MMIT’s Biosimilars Special Report for a holistic view of biosimilars utilization, management and contracting, contact

AIS Health Staff

Related Posts
November 18

FDA Grants Interchangeable Status to Humira Biosimilar, but Certain Factors May Hamper Its, Other Adalimumabs’ Uptake

Read More
November 18

Oncologists Show Interest in Prescribing New CML STAMP Inhibitor Scemblix

Read More
November 18

Eli Lilly Pounces on Flailing Aduhelm With Competing Drug

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today